-

Simulations Plus Sets Date for First Quarter Fiscal Year 2021 Earnings Release and Conference Call

Conference call to be on Monday, January 11, 2021, at 4:15 p.m. ET

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the first quarter of fiscal year 2021, ended November 30, 2020, after the close of the financial markets on Monday, January 11, 2021.

The Company will host a conference call on January 11, 2021, at 4:15 p.m. Eastern Time. All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website under Conference Calls & Presentations. A replay of the webcast will be available on the website approximately one hour following the call.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn | YouTube

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com

Hayden IR
Mr. Cameron Donahue
651-653-1854
slp@haydenir.com

Simulations Plus, Inc.

NASDAQ:SLP

Release Summary
Simulations Plus announced today that it will report its first quarter fiscal year 2021 results on Monday, Jan. 11, 2021, with a webcast at 4:15 pm ET
Release Versions

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com

Hayden IR
Mr. Cameron Donahue
651-653-1854
slp@haydenir.com

Social Media Profiles
More News From Simulations Plus, Inc.

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration’s (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the i...

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements

RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the function...

Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024....
Back to Newsroom